SymBio Pharmaceuticals : Revision to Earnings Forecast for FY 2022

August 4, 2022

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director

President and Chief Executive Officer

(Securities Code: 4582)

Revision to Earnings Forecast for FY 2022

TOKYO, Japan, August 4, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the "Company") today announced that the Company's Board of Directors today approved the following revision to the Earnings Forecast for fiscal year ending December 31, 2022. The Earnings Forecast was previously announced on February 10, 2022. The revision reflects the Company's current performance trends and outlook.

1. Revision to Earnings Forecast for FY 2022 (January 1, 2022 to December 31, 2022)

		Operating	Ordinary	Profit	Earnings
	Net Sales	attributable to
	Profit	Profit	per share
		owners of parent
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Forecast (A)	10,992	1,770	1,750	1,480	38.63
Actual (B)	10,003	1,770	1,750	1,480	38.35
Difference (B-A)	(989)	－	－	－	－
Percentage Change (%)	(9.0)	－	－	－	－
[Reference] Prior Year
Results (FY 2021)	－	－	－	－	－

＊The Company's results for the previous fiscal year were on a non-consolidated basis.

	Net Sales	Operating	Ordinary	Net	Earnings
	Profit	Profit	Profit	per share
[Reference] Prior Year	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Results (FY 2021)	8,256	1,016	1,001	2,032	53.04

2. Reasons for changes

The Company reduced its initial projection for sales by 989 million yen to 10,003 million yen in light of delays in treatments and constraints in sales activities caused by continuing restrictions on visits to medical institutions due to the spread of COVID-19 and the NHI price listing of a generic drug in June

1

2022. The Company maintains its initial forecast for all profit categories, which are operating profit of 1,770 million yen, ordinary profit of 1,750 million yen, and profit attributable to owners of the parent of 1,480 million yen. The profit targets are unchanged as the Company anticipates the impact of lower sales to be offset by reduced SG&A expense while maintaining the highest priority on R&D investment in the Company's global development plan for antiviral drug brincidofovir.

*Earnings forecasts, financial projections, and other forecasts or forward looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to business, economic, financial, or other assumptions and conditions.

[Contact]

Investor Relations

Tel: [phone]

2